dantrolene has been researched along with Aura in 8 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this two-phase study, 21 pediatric patients with epilepsy and spasticity were initially treated with dantrolene sodium suspension and, after a washout period, began a double-blind portion where one half received dantrolene sodium suspension and the other half received a placebo suspension." | 9.04 | Effect of dantrolene sodium on the incidence of seizures in children with spasticity. ( Nogen, AG, 1979) |
| "Status epilepticus is a clinical emergency that can lead to the development of acquired epilepsy following neuronal injury." | 5.36 | Dantrolene inhibits the calcium plateau and prevents the development of spontaneous recurrent epileptiform discharges following in vitro status epilepticus. ( Carter, DS; DeLorenzo, RJ; Deshpande, LS; Nagarkatti, N, 2010) |
| "Dantrolene has an inhibitory action against Ca(2+) release from intracellular Ca(2+) stores." | 5.33 | Dantrolene, a calcium-induced calcium release inhibitor, prevents the acquisition of amygdaloid kindling in rats, a model of experimental epilepsy. ( Sakai, T; Yoshida, M, 2006) |
| "In this two-phase study, 21 pediatric patients with epilepsy and spasticity were initially treated with dantrolene sodium suspension and, after a washout period, began a double-blind portion where one half received dantrolene sodium suspension and the other half received a placebo suspension." | 5.04 | Effect of dantrolene sodium on the incidence of seizures in children with spasticity. ( Nogen, AG, 1979) |
| "We report the effects of two new dihydropyridine derivatives, isradipine (4-(4'-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedic arboxylic acid methylisopropylester) and niguldipine (1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid 3-(4,4-diphenyl-1-piperidinyl)-propyl methyl ester hydrochloride), and of dantrolene (1-[(5-[p-nitrophenyl]furfurylidene)-amino]hydantoin sodium, an inhibitor of Ca2+ release from intracellular stores) on the protective efficacy of antiepileptic drugs against maximal electroshock-induced seizures." | 3.69 | Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice. ( Borowicz, KK; Czuczwar, SJ; Gasior, M; Kleinrok, Z, 1997) |
| "Status epilepticus is a clinical emergency that can lead to the development of acquired epilepsy following neuronal injury." | 1.36 | Dantrolene inhibits the calcium plateau and prevents the development of spontaneous recurrent epileptiform discharges following in vitro status epilepticus. ( Carter, DS; DeLorenzo, RJ; Deshpande, LS; Nagarkatti, N, 2010) |
| "Dantrolene has an inhibitory action against Ca(2+) release from intracellular Ca(2+) stores." | 1.33 | Dantrolene, a calcium-induced calcium release inhibitor, prevents the acquisition of amygdaloid kindling in rats, a model of experimental epilepsy. ( Sakai, T; Yoshida, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nagarkatti, N | 1 |
| Deshpande, LS | 1 |
| Carter, DS | 1 |
| DeLorenzo, RJ | 1 |
| Rutecki, PA | 1 |
| Sayin, U | 1 |
| Yang, Y | 1 |
| Hadar, E | 1 |
| Mazarati, A | 1 |
| Lundström, L | 1 |
| Sollenberg, U | 1 |
| Shin, D | 1 |
| Langel, U | 1 |
| Sankar, R | 1 |
| Yoshida, M | 1 |
| Sakai, T | 1 |
| Delacour, JL | 1 |
| Daoudal, P | 1 |
| Chapoutot, JL | 1 |
| Rocq, B | 1 |
| Borowicz, KK | 1 |
| Gasior, M | 1 |
| Kleinrok, Z | 1 |
| Czuczwar, SJ | 1 |
| Yang, L | 1 |
| Benardo, LS | 1 |
| Nogen, AG | 1 |
1 trial available for dantrolene and Aura
| Article | Year |
|---|---|
Effect of dantrolene sodium on the incidence of seizures in children with spasticity.
Topics: Adolescent; Anticonvulsants; Cerebral Palsy; Child; Child, Preschool; Clinical Trials as Topic; Dant | 1979 |
7 other studies available for dantrolene and Aura
| Article | Year |
|---|---|
Dantrolene inhibits the calcium plateau and prevents the development of spontaneous recurrent epileptiform discharges following in vitro status epilepticus.
Topics: Animals; Calcium; Cell Death; Cells, Cultured; Dantrolene; Dizocilpine Maleate; Epilepsy; Excitatory | 2010 |
Determinants of ictal epileptiform patterns in the hippocampal slice.
Topics: Animals; Calcium; Calcium Channels, L-Type; Dantrolene; Electrophysiology; Enzyme Inhibitors; Epilep | 2002 |
Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: The effects of subtype-selective agonists and the role of G-protein-mediated signaling.
Topics: Animals; Anticonvulsants; Bee Venoms; Calcium Signaling; Dantrolene; Electric Stimulation; Epilepsy; | 2006 |
Dantrolene, a calcium-induced calcium release inhibitor, prevents the acquisition of amygdaloid kindling in rats, a model of experimental epilepsy.
Topics: Animals; Calcium; Dantrolene; Disease Models, Animal; Epilepsy; Kindling, Neurologic; Male; Rats; Ra | 2006 |
[Therapy of neuroleptic malignant syndrome with dantrolene].
Topics: Adult; Antipsychotic Agents; Dantrolene; Epilepsy; Humans; Male; Nervous System Diseases; Syndrome | 1981 |
Influence of isradipine, niguldipine and dantrolene on the anticonvulsive action of conventional antiepileptics in mice.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1997 |
Epileptogenesis following neocortical trauma from two sources of disinhibition.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Calcium; Cell Membrane; Chelating Agents; Dantrolene; | 1997 |